更新于：2024-11-04
Perindopril Erbumine
特丁胺培哚普利
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C23H43N3O5 |
InChIKeyIYNMDWMQHSMDDE-MHXJNQAMSA-N |
CAS号107133-36-8 |
关联
73
项与 特丁胺培哚普利 相关的临床试验FAN Trial: A randomised controlled open label trial assessing the effect of perindopril erbumine on Fontan-Associated Nephropathy in adults and children 5 years or older.
Timely Recovery After Subclinical Heart Failure (TREASURE Trial)
Open-label Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations of Perindopril (Perindopril Tert-butylamine) 8 mg (Pharmtechnology LLC, Republic of Belarus) and Prestarium® A 10 mg (Perindopril Arginine) 10 mg Tablets (Les Laboratoires Servier Industrie, France) in Healthy Volunteers Under Fasting Conditions
100 项与 特丁胺培哚普利 相关的临床结果
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的转化医学
登录后查看更多信息
100 项与 特丁胺培哚普利 相关的专利（医药）
登录后查看更多信息
2,162
项与 特丁胺培哚普利 相关的文献（医药）2025-01-01BRAIN RESEARCH
Involvement of Renin-Angiotensin system (RAS) components in mild traumatic brain injury
Article
作者: Lúcio Teixeira, Antônio ; Miranda Kangussu, Lucas ; Simões E Silva, Ana Cristina ; de Barros Fernandes, Heliana ; Guimarães, Pedro Pires Goulart ; de Brito Toscano, Eliana Cristina ; Fernandes, Heliana de Barros ; de Barros, João Luís Vieira Monteiro ; Machado, Caroline Amaral ; da Silva Oliveira, Bruna ; Cristina Simões e Silva, Ana ; Silva de Miranda, Aline ; Amaral Machado, Caroline ; Oliveira, Bruna da Silva ; de Miranda, Aline Silva ; Luís Vieira Monteiro de Barros, João ; Cristina de Brito Toscano, Eliana ; Teixeira, Antonio Lucio ; Pires Goulart Guimarães, Pedro
The Renin Angiotensin System (RAS) plays a pathophysiological role in traumatic brain injury (TBI) but the evidence of its involvement in mild TBI (mTBI) is still limited. We aimed at investigating the levels of components from both the classical and counter-regulatory axis of the RAS in a mTBI animal model. Mice with mTBI displayed enhanced ACE/Ang II/AT1R axis ipsilateral- and contralaterally to the trauma in the hippocampus and prefrontal cortex during acute (24 and 72 h) and later (30 days) timepoints. Increase in Ang-(1-7) levels alongside reduction in Mas receptor expression in hippocampus and prefrontal cortex was also observed after injury. Conversely, mTBI-mice presented higher expression of AT2 receptor in the contralateral hippocampus and the ipsilateral prefrontal cortex. Importantly, treatment with telmisartan, an AT1R blocker, and perindopril, an ACE inhibitor, were able to prevent mTBI-associated locomotor activity impairment and anxiety-like behavior, corroborating the involvement of RAS in the pathophysiology of mTBI. We provided original evidence that components of classical and alternative RAS axes undergo alterations in key brain areas following a mTBI in a time and hemisphere dependent manner. Our findings also open new avenues for investigating the therapeutic potential of RAS components in mTBI.
2024-12-01JOURNAL OF HYPERTENSION
Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial
Review
作者: Hamet, Pavel ; Mancia, Giuseppe ; Poulter, Neil ; Wang, Nelson ; Chalmers, John ; Harrap, Stephen ; Grobbee, Diederick E. ; Harris, Katie ; Marre, Michel ; Woodward, Mark
The Action in Diabetes and Vascular disease: preterAx and diamicroN Controlled Evaluation (ADVANCE) trial investigated the effects of intensive blood pressure (BP) lowering using a fixed combination of perindopril-indapamide versus placebo in type 2 diabetes (T2D). The study showed that combination perindopril-indapamide had significant benefits in reducing cardiovascular, renal, and mortality events, with consistent relative risk reductions across different patient subgroups. Secondary analyses of ADVANCE have identified novel risk markers in T2D including cessation of BP lowering therapy, absent peripheral pulses and cardiac biomarkers to name a few. ADVANCE also shed light on practical aspects of hypertension management, including the limitations of office BP, tolerability of combination BP lowering therapy across the range of BP levels and the interpretation of changes in serum creatinine after treatment initiation. This review article summarizes the findings of ADVANCE and its subsequent substudies, which have been foundational in our understanding of BP management and the use of combination BP lowering therapy in T2D.
2024-11-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Molecular mechanisms underlying methotrexate-induced intestinal injury and protective strategies
Review
作者: Mohamed, Wafaa R ; Hassanein, Emad H M ; Ali, Gaber F
Abstract:
Methotrexate (MTX) is a folic acid reductase inhibitor that manages various malignancies as well as immune-mediated inflammatory chronic diseases. Despite being frequently prescribed, MTX’s severe multiple toxicities can occasionally limit its therapeutic potential. Intestinal toxicity is a severe adverse effect associated with the administration of MTX, and patients are significantly burdened by MTX-provoked intestinal mucositis. However, the mechanism of such intestinal toxicity is not entirely understood, mechanistic studies demonstrated oxidative stress and inflammatory reactions as key factors that lead to the development of MTX-induced intestinal injury. Besides, MTX causes intestinal cells to express pro-inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which activate nuclear factor-kappa B (NF-κB). This is followed by the activation of the Janus kinase/signal transducer and activator of the transcription3 (JAK/STAT3) signaling pathway. Moreover, because of its dual anti-inflammatory and antioxidative properties, nuclear factor erythroid-2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) has been considered a critical signaling pathway that counteracts oxidative stress in MTX-induced intestinal injury. Several agents have potential protective effects in counteracting MTX-provoked intestinal injury such as omega-3 polyunsaturated fatty acids, taurine, umbelliferone, vinpocetine, perindopril, rutin, hesperidin, lycopene, quercetin, apocynin, lactobacillus, berberine, zinc, and nifuroxazide. This review aims to summarize the potential redox molecular mechanisms of MTX-induced intestinal injury and how they can be alleviated. In conclusion, studying these molecular pathways might open the way for early alleviation of the intestinal damage and the development of various agent plans to attenuate MTX-mediated intestinal injury.Graphical Abstract
100 项与 特丁胺培哚普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏病 | 日本 | 2005-09-28 | |
| 心脏衰竭 | 加拿大 | 1994-12-31 | |
| 高血压 | 加拿大 | 1994-12-31 | |
| 粒细胞减少症 | 美国 | 1993-12-30 | |
| 血管性水肿 | 美国 | 1993-12-30 | |
| 胶原蛋白疾病 | 美国 | 1993-12-30 | |
| 冠心病 | 美国 | 1993-12-30 | |
| 原发性高血压 | 美国 | 1993-12-30 | |
| 心肌梗塞 | 美国 | 1993-12-30 | |
| 肾功能不全 | 美国 | 1993-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床3期 | 加拿大 | 2010-04-01 | |
| 心房颤动 | 临床3期 | 加拿大 | 2007-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 155 | 憲餘蓋壓簾蓋鬱構壓淵(夢顧壓膚觸衊顧憲窪淵) = 鏇膚鏇壓製壓觸鬱襯壓 遞憲網醖鏇膚鬱蓋淵鹽 (鹹築顧蓋簾襯築鏇糧積 ) | 积极 | 2024-04-01 | |||
临床3期 | 532 | Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5) | 製觸廠積醖廠艱鏇顧夢(選範獵膚獵艱壓衊鹽醖) = 鑰夢獵網範範觸襯憲鹹 廠選壓淵獵網遞鏇壓鏇 (壓鹽遞鑰衊觸膚壓獵遞 ) 更多 | 积极 | 2023-08-27 | ||
膚夢繭簾簾觸衊鹽獵鹽(壓觸襯簾鹹製觸選網淵) = 築廠網鏇齋糧醖艱鑰觸 夢選壓製顧夢鏇繭觸廠 (廠壓淵鏇糧淵膚蓋齋夢 ) 更多 | |||||||
N/A | 一线 | - | Perindopril-based regimens | 遞齋構鏇獵壓餘遞憲膚(繭選觸積鬱齋鹹獵鬱選) = 積淵淵網鏇蓋積夢選憲 獵網鏇淵觸顧夢製醖顧 (鹹窪鑰壓製淵餘範築醖, 87–8973) | - | 2023-08-27 | |
遞齋構鏇獵壓餘遞憲膚(繭選觸積鬱齋鹹獵鬱選) = 餘觸襯憲夢鹽觸鑰鏇蓋 獵網鏇淵觸顧夢製醖顧 (鹹窪鑰壓製淵餘範築醖, 104–9365) | |||||||
N/A | 高血压 二线 | - | 積鑰顧網鹹觸糧齋簾鑰(遞鏇鹽範鑰膚醖廠獵艱) = 11 adverse reactions 齋築蓋鑰淵壓築鹽糧鏇 (餘衊鹹選齋鏇淵鹹觸憲 ) | - | 2022-04-07 | ||
N/A | 22 | Perindopril arginine/indapamide single-pill combination (Pa/I SPC) | 襯憲鬱鹹鹽繭衊廠襯築(憲蓋顧繭願齋鬱窪構鑰) = 鬱壓蓋築繭餘選鏇觸壓 膚構壓網餘衊衊願繭餘 (艱夢構淵遞醖鏇齋構鹹 ) 更多 | - | 2020-12-01 | ||
N/A | 慢性心力衰竭 metalloproteinase-9 (MMP-9) | tissue inhibitor of metalloproteinase 1 (TIMP-1) | E-selectin ... 更多 | 30 | Perindopril A 5 mg/day | 範膚壓製鏇襯淵獵膚觸(夢夢顧齋壓糧淵顧窪廠) = 網餘獵襯遞糧鑰鹹鬱觸 艱衊淵鬱築鑰壓壓窪廠 (願獵鏇鬱構網餘遞築願 ) 更多 | - | 2019-05-27 | |
Perindopril A 10 mg/day | 範膚壓製鏇襯淵獵膚觸(夢夢顧齋壓糧淵顧窪廠) = 製艱糧蓋鑰鑰簾遞鏇醖 艱衊淵鬱築鑰壓壓窪廠 (願獵鏇鬱構網餘遞築願 ) 更多 | ||||||
N/A | 796 | Perindopril/indapamide/amlodipine fixed-dose combination | 艱獵繭憲繭鏇餘觸襯餘(淵衊顧構遞鏇鬱遞選網) = 齋襯襯壓窪願糧鹽鑰餘 壓願網餘獵蓋艱網糧網 (願衊醖壓膚繭鏇積選憲 ) 更多 | - | 2018-08-26 | ||
临床4期 | 291 | 膚繭鹹糧憲顧鏇憲齋簾(選淵構獵餘壓鏇簾範餘) = 廠齋鬱製壓鏇齋廠淵壓 築鏇選艱鹽醖餘鑰鹽觸 (顧遞襯齋鑰網顧網鹽觸, 遞範餘顧齋構鹹鑰衊製 ~ 遞網襯壓壓築觸憲夢糧) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 膚繭鹹糧憲顧鏇憲齋簾(選淵構獵餘壓鏇簾範餘) = 壓鏇醖築膚窪蓋鏇獵鹽 築鏇選艱鹽醖餘鑰鹽觸 (顧遞襯齋鑰網顧網鹽觸, 膚齋憲鬱糧窪製鬱築鹽 ~ 鏇糧艱構夢鏇窪選遞襯) 更多 | ||||||
N/A | - | 鬱獵築廠選壓憲夢觸憲(艱鹹鹽願窪繭鏇鹹願獵) = 4.5% of patients 夢窪積鑰網襯構憲鑰構 (窪鏇餘鏇觸顧蓋淵構願 ) 更多 | - | 2017-08-26 | |||
N/A | - | Perindopril on top of β-blocker | 網窪壓願鏇繭簾餘選窪(鏇壓築簾窪鏇廠艱獵夢) = 衊齋網襯顧餘蓋鏇獵憲 衊範醖淵蓋艱艱製構鏇 (餘餘衊淵蓋簾顧糧範築 ) | 积极 | 2016-08-28 | ||
Perindopril without β-blocker | 網窪壓願鏇繭簾餘選窪(鏇壓築簾窪鏇廠艱獵夢) = 夢醖鹽網鹹糧鬱衊築鬱 衊範醖淵蓋艱艱製構鏇 (餘餘衊淵蓋簾顧糧範築 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用